View Future GrowthEnveric Biosciences 過去の業績過去 基準チェック /06Enveric Biosciences は平均年間 16.5% の収益成長を遂げていますが、Pharmaceuticals 業界では年間 収益成長率 となっています。8.7% です。主要情報16.54%収益成長率84.14%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率n/a株主資本利益率-209.98%ネット・マージンn/a前回の決算情報31 Dec 2025最近の業績更新更新なしすべての更新を表示Recent updatesEnveric Biosciences, Inc. announced that it expects to receive $5.000002 million in fundingApr 17Enveric Biosciences, Inc., Annual General Meeting, May 28, 2026Apr 15Enveric Biosciences Reports Eb-003 Bret Receptor Engagement Assay DataFeb 20Enveric Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $1.450017 million.Jan 29Enveric Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $1.450017 million.Jan 28Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug CandidatesDec 09Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug CandidatesNov 27Enveric Biosciences, Inc Receives Delisting Notice from NasdaqOct 24Enveric Biosciences Hires Ip Powerhouse to Defend Its U.S. Patent with Claims Relevant to BretisilocinOct 15Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical TrialsOct 03Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND SubmissionSep 16Enveric Biosciences, Inc. Receives Notice of Nasdaq Listing DeficiencyAug 30Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric IndicationsAug 28Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)Jul 15Enveric Biosciences Announces Data That Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003Jun 24Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric DisordersJun 10Enveric Biosciences, Inc. Reports Positive Preclinical Results for Lead Drug Candidate EB-003May 28Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative DiseaseMay 20Enveric Biosciences, Inc., Annual General Meeting, May 29, 2025Apr 16Enveric Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $1.854151 million.Apr 10Enveric Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $4.999954 million.Feb 04Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark OfficeJan 31Enveric Biosciences, Inc. has filed a Follow-on Equity Offering.Jan 15Enveric Biosciences Announces Completion of Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-Like BehaviorNov 26The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric BiosciencesNov 24New major risk - Financial position Nov 17Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003Oct 15New major risk - Financial position Aug 01Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to Be Dosed OrallyJul 26An Intrinsic Calculation For Enveric Biosciences, Inc. (NASDAQ:ENVB) Suggests It's 40% UndervaluedJul 02Enveric Biosciences Regains Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(b)(1)May 25Enveric Biosciences Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Marketplace Rule 5550(a)(2)May 18New major risk - Financial position May 17Enveric Biosciences, Inc., Annual General Meeting, May 28, 2024Apr 17New major risk - Revenue and earnings growth Mar 26New major risk - Shareholder dilution Mar 11Enveric Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $0.322453 million.Mar 11New major risk - Share price stability Feb 29Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health DisordersFeb 22Enveric Biosciences Receives Notice from the Nasdaq Stock MarketFeb 09Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 SeriesDec 28Enveric Biosciences Selects Development Candidates from Evm301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived CompoundsDec 06Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal ChemistryNov 29Enveric Biosciences Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock MarketNov 23Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373Oct 19Enveric Biosciences, Inc., Annual General Meeting, Nov 02, 2023Sep 19Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical ProgramAug 22Enveric Biosciences, Inc. Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373Jul 25Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373Jul 18Enveric Biosciences, Inc. Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up ManufacturingJun 28Enveric Biosciences, Inc. Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health DisordersMay 24Enveric Biosciences, Inc. Receives Notice of Allowance from Uspto for Novel Prodrug of PsilocinMay 19High number of new and inexperienced directors Nov 16Enveric Biosciences to raise $8M in stock offering for corporate use Jul 25High number of new and inexperienced directors Apr 27Enveric Biosciences Inc. Appoints Dr. Marcus Schabacker to Board of DirectorsJan 06収支内訳Enveric Biosciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:ENVB 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 250-126330 Sep 250-116330 Jun 250-106431 Mar 250-96331 Dec 240-106330 Sep 240-105430 Jun 240-116431 Mar 240-158631 Dec 230-179730 Sep 230-2311730 Jun 230-2313831 Mar 230-1912831 Dec 220-1912830 Sep 220-5218930 Jun 220-5216831 Mar 220-5016731 Dec 210-4920530 Sep 210-1114230 Jun 210-913131 Mar 210-911031 Dec 200-75030 Sep 200-32030 Jun 200-32031 Mar 200-33031 Dec 190-22030 Sep 190-33031 Dec 180-220質の高い収益: ENVBは現在利益が出ていません。利益率の向上: ENVBは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ENVBは利益を出していないが、過去 5 年間で年間16.5%の割合で損失を削減してきた。成長の加速: ENVBの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: ENVBは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -3.3% ) と比較することは困難です。株主資本利益率高いROE: ENVBは現在利益が出ていないため、自己資本利益率 ( -209.98% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/03 22:15終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Enveric Biosciences, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Vernon BernardinoH.C. Wainwright & Co.
Enveric Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $1.450017 million.Jan 29
Enveric Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $1.450017 million.Jan 28
Enveric Biosciences Hires Ip Powerhouse to Defend Its U.S. Patent with Claims Relevant to BretisilocinOct 15
Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical TrialsOct 03
Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric IndicationsAug 28
Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)Jul 15
Enveric Biosciences Announces Data That Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003Jun 24
Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric DisordersJun 10
Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative DiseaseMay 20
Enveric Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $1.854151 million.Apr 10
Enveric Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $4.999954 million.Feb 04
Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark OfficeJan 31
Enveric Biosciences Announces Completion of Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-Like BehaviorNov 26
The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric BiosciencesNov 24
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to Be Dosed OrallyJul 26
An Intrinsic Calculation For Enveric Biosciences, Inc. (NASDAQ:ENVB) Suggests It's 40% UndervaluedJul 02
Enveric Biosciences Regains Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(b)(1)May 25
Enveric Biosciences Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Marketplace Rule 5550(a)(2)May 18
Enveric Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $0.322453 million.Mar 11
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health DisordersFeb 22
Enveric Biosciences Selects Development Candidates from Evm301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived CompoundsDec 06
Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal ChemistryNov 29
Enveric Biosciences Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock MarketNov 23
Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373Oct 19
Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical ProgramAug 22
Enveric Biosciences, Inc. Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373Jul 25
Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373Jul 18
Enveric Biosciences, Inc. Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up ManufacturingJun 28
Enveric Biosciences, Inc. Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health DisordersMay 24
Enveric Biosciences, Inc. Receives Notice of Allowance from Uspto for Novel Prodrug of PsilocinMay 19
